Sorachai Nitayaphan

Research interests

Publications

• Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1508952

• COMPASS identifies T-cell subsets correlated with clinical outcomes

  Nature Biotechnology · 2015 · https://doi.org/10.1038/nbt.3187

• Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

  PLoS ONE · 2014 · https://doi.org/10.1371/journal.pone.0087572

• Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

  Science Translational Medicine · 2014 · https://doi.org/10.1126/scitranslmed.3007730

• Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

  Science Translational Medicine · 2014 · https://doi.org/10.1126/scitranslmed.3007736

• Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

  Immunity · 2013 · https://doi.org/10.1016/j.immuni.2012.11.011

• Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

  PLoS ONE · 2013 · https://doi.org/10.1371/journal.pone.0075665

• Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

  Proceedings of the National Academy of Sciences · 2013 · https://doi.org/10.1073/pnas.1301456110

• Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

  Nature · 2012 · https://doi.org/10.1038/nature11519

• Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

  The Lancet Infectious Diseases · 2012 · https://doi.org/10.1016/s1473-3099(12)70088-9

• Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

  Journal of Virology · 2012 · https://doi.org/10.1128/jvi.01023-12

• The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

  AIDS Research and Human Retroviruses · 2012 · https://doi.org/10.1089/aid.2012.0103

• Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

  The Journal of Infectious Diseases · 2012 · https://doi.org/10.1093/infdis/jis367

• Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1113425

• Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0908492

Current projects

No projects listed.